A Phase 1 interventional study of BI 1015550 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objectives of this trial are to investigate pharmacokinetics, safety and tolerability of BI 1015550 in Chinese healthy male and female subjects following administration of single doses.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Chinese subjects will only be included in the trial if they meet the following criteria:
Exclusion criteria
Subjects will not be allowed to participate, if any of the following general criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single film-coated tablet of 9 milligram BI 1015550 taken orally after an overnight fast of at least 10 hours.
Drug: BI 1015550
A single film-coated tablet of 18 milligram BI 1015550 taken orally after an overnight fast of at least 10 hours.
Drug: BI 1015550
A single film-coated tablet BI 1015550 taken orally after an overnight fast of at least 10 hours.
Also known as: Nerandomilast, JASCAYD®
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).
Time frame: Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hours following drug administration.
Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)
Maximum measured concentration of BI 1015550 in plasma (Cmax).
Time frame: Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hours following drug administration.
Number of Subjects With Any Treatment-emergent Adverse Event (AE)
Number of subjects with any treatment-emergent adverse event (AE).
Time frame: Up to 7 days.
This was a non-randomised, uncontrolled, open label, single-dose, parallel-group design trial.
| Milestone | BI 1015550 9 mg | BI 1015550 18 mg |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).
| Nanomol*Hour/Liter | BI 1015550 9 mg | BI 1015550 18 mg |
|---|---|---|
| Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 1780 ± 19.1 | 3680 ± 32.6 |
Maximum measured concentration of BI 1015550 in plasma (Cmax).
| Nanomol/Liter | BI 1015550 9 mg | BI 1015550 18 mg |
|---|---|---|
| Maximum Measured Concentration of BI 1015550 in Plasma (Cmax) | 325 ± 30.3 | 591 ± 39.0 |
Number of subjects with any treatment-emergent adverse event (AE).
| Participants | BI 1015550 9 mg | BI 1015550 18 mg |
|---|---|---|
| Number of Subjects With Any Treatment-emergent Adverse Event (AE) | 2 | 6 |
Collected over Adverse events: Up to 7 days. All-cause mortality: Up to 14 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BI 1015550 9 mg | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| BI 1015550 18 mg | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Event | BI 1015550 9 mg | BI 1015550 18 mg |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/12 | 2/12 |
| White blood cells urine positiveInvestigations | 0/12 | 2/12 |
| Aspartate aminotransferase increasedInvestigations | 0/12 | 1/12 |
| Basophil count increasedInvestigations | 0/12 | 1/12 |
| C-reactive protein increasedInvestigations | 1/12 | 0/12 |
| Eosinophil count increasedInvestigations | 0/12 | 1/12 |
| Gamma-glutamyltransferase increasedInvestigations | 0/12 | 1/12 |
| Neutrophil count increasedInvestigations | 0/12 | 1/12 |
| Urinary occult blood positiveInvestigations | 1/12 | 0/12 |
| White blood cell count increasedInvestigations | 0/12 | 1/12 |
Treated set (TS): The treated set included all subjects who were treated with at least one dose of trial drug.
| Age, Continuous(years) | BI 1015550 9 mg | BI 1015550 18 mg | Total |
|---|---|---|---|
| Mean | 36.7 ± 4.9 | 29.8 ± 1.9 | 33.3 ± 5.0 |
| Sex: Female, Male(Participants) | BI 1015550 9 mg | BI 1015550 18 mg | Total |
|---|---|---|---|
| Female | 6 | 5 | 11 |
| Male | 6 | 7 | 13 |
| Ethnicity (NIH/OMB)(Participants) | BI 1015550 9 mg | BI 1015550 18 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 12 | 12 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | BI 1015550 9 mg | BI 1015550 18 mg | Total |
|---|---|---|---|
| Asian Indian | 0 | 0 | 0 |
| Chinese | 12 | 12 | 24 |
| Japanese | 0 | 0 | 0 |
| Korean | 0 | 0 | 0 |
| Other Asian | 0 | 0 | 0 |
| Southeast Asian | 0 | 0 | 0 |
| Taiwanese | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Jan 2023 to primary completion in Mar 2023, 2 months.
Results were first posted in Nov 2025, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nerandomilast